PlainPharmaWatch
CMS PY 2024 Company profile Open Payments data

LONGEVITI NEURO SOLUTIONS LLC

LONGEVITI NEURO SOLUTIONS LLC reported $100.4K in payments to physicians and teaching hospitals across 68 transactions in CMS Open Payments PY 2024.

Pharmaceutical payment transparency data for LONGEVITI NEURO SOLUTIONS LLC. Ranked #1107 of 1,797 companies by total payments. Source: CMS Open Payments, Program Year 2024.

Payment Overview

Total Payments

$100.4K

0.0% of all payments

Transactions

68

$1.5K avg

Recipients

65

$1.5K avg

Industry Rank

#1107

of 1,797 companies

What the Data Shows for LONGEVITI NEURO SOLUTIONS LLC

In Program Year 2024, LONGEVITI NEURO SOLUTIONS LLC reported $100,369.32 in payments to 65 physicians and teaching hospitals across 68 individual transactions — an average of $1.5K per transaction and $1.5K per recipient. That total places LONGEVITI NEURO SOLUTIONS LLC at rank #1107 out of 1,797 companies in the CMS Open Payments database, representing 0.0% of all industry payments reported nationwide for the year. Payment volume at this scale is characteristic of manufacturers with broad prescriber engagement, active clinical research programs, or patented therapies generating ongoing royalty obligations.

The payment mix for LONGEVITI NEURO SOLUTIONS LLC spans 7 distinct categories defined by CMS — including general payments (consulting, speaker fees, meals, travel), research payments tied to clinical trials, and ownership or investment interests. The largest single category is "Consulting Fee" at $34.9K, accounting for 34.7% of the company's reported total and 10 transactions. This distribution matters because different payment types carry different regulatory and ethical implications: research funding supports clinical development, while general payments like meals and speaker fees have been studied for their correlation with prescribing patterns in peer-reviewed journals such as JAMA Internal Medicine.

Recipient concentration is another useful lens. The top 5 recipients of payments from LONGEVITI NEURO SOLUTIONS LLC received $0.00 combined — 0.0% of the company's total — with the remaining 100.0% distributed across the rest of the 65 recipients. A relatively distributed top-5 share suggests broader engagement across the prescriber community rather than concentration among a handful of high-value relationships. All figures above are drawn directly from the CMS Open Payments Public Use Files for PY2024 and are disclosed under the Physician Payments Sunshine Act; this page summarizes reported financial transfers and does not represent medical advice or judgment about individual prescribing decisions.

Payment Breakdown by Type

LONGEVITI NEURO SOLUTIONS LLC made 7 types of payments. "Consulting Fee" accounts for 34.7%.

Consulting Fee $34.9K

34.7% · 10 transactions

Travel and Lodging $9.0K

9.0% · 7 transactions

Grant $6.0K

6.0% · 1 transactions

Food and Beverage $5.1K

5.1% · 43 transactions

Honoraria $2.0K

2.0% · 2 transactions

Compensation for Faculty or Speaker (Medical Education) $1.5K

1.5% · 1 transactions

Royalty or License $1.4K

1.3% · 1 transactions

Payment Type Amount Transactions
Consulting Fee $34.9K 10
Travel and Lodging $9.0K 7
Grant $6.0K 1
Food and Beverage $5.1K 43
Honoraria $2.0K 2
Compensation for Faculty or Speaker (Medical Education) $1.5K 1
Royalty or License $1.4K 1

Payment Size Analysis

Average transaction size: $1.5K. Average per recipient: $1.5K.

Total Amount

$100,369.32

Avg per Transaction

$1.5K

Avg per Recipient

$1.5K

Payment Transparency Context

The Physician Payments Sunshine Act (part of the Affordable Care Act) requires pharmaceutical and medical device manufacturers to report payments and transfers of value to physicians and teaching hospitals. These payments can include consulting fees, research grants, speaker fees, food and beverages, travel, royalties, and other forms of compensation.

Industry Total (2024)

$13.3B

across 1,797 companies

LONGEVITI NEURO SOLUTIONS LLC Share

0.0%

#1107 by total payments

Frequently Asked Questions

How much did LONGEVITI NEURO SOLUTIONS LLC pay to physicians and hospitals in 2024?
LONGEVITI NEURO SOLUTIONS LLC made $100,369.32 in payments to physicians and hospitals in Program Year 2024, across 68 individual transactions. This represents 0.0% of all industry payments reported to CMS Open Payments.
How many physicians received payments from LONGEVITI NEURO SOLUTIONS LLC?
LONGEVITI NEURO SOLUTIONS LLC made payments to 65 physicians and teaching hospitals in 2024. The average payment per recipient was $1.5K.
What types of payments did LONGEVITI NEURO SOLUTIONS LLC make?
LONGEVITI NEURO SOLUTIONS LLC made 7 different types of payments. The largest category was "Consulting Fee" at $34.9K, representing 34.7% of all payments.
How does LONGEVITI NEURO SOLUTIONS LLC rank among pharmaceutical companies?
LONGEVITI NEURO SOLUTIONS LLC ranks #1107 out of 1,797 companies by total payment amount in the CMS Open Payments database for 2024.
What is the average payment size from LONGEVITI NEURO SOLUTIONS LLC?
The average transaction from LONGEVITI NEURO SOLUTIONS LLC was $1.5K in 2024. The company made 68 total transactions to 65 recipients.
Are the top recipients concentrated for LONGEVITI NEURO SOLUTIONS LLC?
The top 5 recipients received $0.00 from LONGEVITI NEURO SOLUTIONS LLC, representing 0.0% of the company's total payments. Payments are relatively well-distributed across recipients.
Where does the payment data for LONGEVITI NEURO SOLUTIONS LLC come from?
This data comes from the CMS Open Payments program (Sunshine Act), which requires pharmaceutical and medical device companies to report payments and transfers of value to physicians and teaching hospitals. The data covers Program Year 2024.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.3B across 1,797 companies.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainPharmaWatch Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.